The Current Ratio as of December 2024 (TTM) for Reneo Pharmaceuticals, Inc. (RPHM) is 57.86

According to Reneo Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 57.86. This represents a change of 124.59% compared to the average of 25.76 of the last 4 quarters.

Reneo Pharmaceuticals, Inc. (RPHM) Historical Current Ratio (quarterly & annually)

How has RPHM Current Ratio performed in the past?

The mean historical Current Ratio of Reneo Pharmaceuticals, Inc. over the last ten years is 11.04. The current 57.86 Current Ratio has changed 52.31% with respect to the historical average. Over the past ten years (40 quarters), RPHM's Current Ratio was at its highest in in the June 2024 quarter at 57.86. The Current Ratio was at its lowest in in the September 2001 quarter at 0.

Reneo Pharmaceuticals, Inc. (RPHM) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Reneo Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Reneo Pharmaceuticals, Inc. (RPHM) Average Current Ratio

How has RPHM Current Ratio performed in the past?

The current Current Ratio of Reneo Pharmaceuticals, Inc. (RPHM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Reneo Pharmaceuticals, Inc. (RPHM) Current Ratio vs. Peers

How is RPHM’s Current Ratio compared to its peers?

Reneo Pharmaceuticals, Inc.’s Current Ratio is greater than Prime Medicine, Inc. (6.50), greater than Ginkgo Bioworks Holdings, Inc. (5.79), greater than Ocean Biomedical, Inc. (0.04), greater than Royalty Pharma plc (1.54), greater than Immix Biopharma, Inc. (3.47), greater than CNS Pharmaceuticals, Inc. (1.82), greater than Hepion Pharmaceuticals, Inc. (1.30), greater than Freeline Therapeutics Holdings plc (1.95), greater than AVROBIO, Inc. (26.17), greater than Summit Therapeutics Inc. (8.31), greater than Nkarta, Inc. (12.91), greater than Cullinan Oncology, Inc. (24.46), greater than Kezar Life Sciences, Inc. (7.65), greater than Kronos Bio, Inc. (8.32), greater than Adaptive Biotechnologies Corporation (3.52), greater than Legend Biotech Corporation (4.98), greater than Vir Biotechnology, Inc. (8.94), greater than Apellis Pharmaceuticals, Inc. (4.36), greater than Werewolf Therapeutics, Inc. (10.10), greater than Edgewise Therapeutics, Inc. (26.35), greater than Decibel Therapeutics, Inc. (4.81), greater than Celcuity Inc. (10.36), greater than C4 Therapeutics, Inc. (6.31),

Build a custom stock screener for Reneo Pharmaceuticals, Inc. (RPHM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Reneo Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Reneo Pharmaceuticals, Inc. (RPHM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Reneo Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.